Company Type
- Top 20 Pharma: 32.9%
- Small/Mid-Tier Pharma: 21.5%
- Emerging Biopharma: 11.4%
- Virtual Pharma: 7.4%
- Generic Pharma: 6.7%
- Top 10 Biopharma: 6.0%
- Specialty Pharma: 5.4%
- Consumer/OTC Healthcare: 1.3%
- Other: 7.4%
Job Function
- R&D: 22.8%
- Purchasing/Sourcing: 12.1%
- Production/Manufacturing/Packaging: 9.4%
- Corporate Management: 8.7%
- QA/QC/Validation: 8.1%
- Project Manager: 7.4%
- Supply Chain Manager: 6.7%
- Contract Manager: 5.4%
- Business Development: 4.7%
- Marketing/Sales: 3.4%
- Clinical Research: 2.7%
- Engineering: 2.0%
- Regulatory Affairs: 0.7%
- Other: 6.0%
Signs of Improvement?
Last year, a whopping 55% of total respondents believed that they'd spend the same or less on outsourcing spending in the coming year; this year, that dipped to 45%.Meanwhile, 51%, told us that they spent the same or less on outsourcing in the previous year, down from 56%in our 2010 survey.
Only 25% of respondents told us they had cancelled outsourcing projects in the previous year due to the economy; down from 35% in our 2010 survey. Half of those respondents said they foresee resuming those projects with the original contract service provider, and 75% of them describe their outsourcing as strategic, not tactical. (Only 56% of all respondents describe their outsourcing relationships as strategic.)